ZS Pharma (FRA:0ZS) Debt-to-EBITDA : -0.07 (As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is ZS Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ZS Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was €2.23 Mil. ZS Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was €6.83 Mil. ZS Pharma's annualized EBITDA for the quarter that ended in Sep. 2015 was €-123.08 Mil. ZS Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 was -0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ZS Pharma's Debt-to-EBITDA or its related term are showing as below:

FRA:0ZS's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.705
* Ranked among companies with meaningful Debt-to-EBITDA only.

ZS Pharma Debt-to-EBITDA Historical Data

The historical data trend for ZS Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZS Pharma Debt-to-EBITDA Chart

ZS Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Debt-to-EBITDA

-0.03

-0.17

ZS Pharma Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Debt-to-EBITDA	Get a 7-Day Free Trial							-0.16	-0.13	-0.12	-0.08	-0.07

Competitive Comparison of ZS Pharma's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, ZS Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZS Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZS Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ZS Pharma's Debt-to-EBITDA falls into.

ZS Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ZS Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.247	+	8.18)	/	-50.423
	=	-0.17

ZS Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.227	+	6.834)	/	-123.084
	=	-0.07

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2015) EBITDA data.

ZS Pharma (FRA:0ZS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

ZS Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ZS Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

ZS Pharma (FRA:0ZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZS Pharma Inc (FRA:0ZS) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Website

http://www.zspharma.com

ZS Pharma Inc was incorporated in Delaware in February 2008. The Company is a biopharmaceutical company engaged in the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It was initially engaged in the development of ZS-9, its product candidate in Phase 3 development for the treatment of hyperkalemia. Hyperkalemia is characterized by elevated levels of potassium in the blood (greater than 5.0 mEq/L) and is a life-threatening condition that occurs frequently in patients with chronic kidney disease (CKD), heart failure, and diabetes. ZS-9 is currently in Phase 3 clinical development. ZS-9 is a therapy to treat hyperkalemia, regardless of the underlying cause, and allows patients to benefit from the cardio-renal protective effect of RAAS therapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address CKD, HF and metabolic diseases. It faces competition from many pharmaceutical and biotechnology companies that are researching and selling products to treat CKD, HF and metabolic diseases. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

ZS Pharma (FRA:0ZS) Headlines

No Headlines